Maillard Reactions in Pharmaceutical Formulations and Human Health
Author(s): Newton David W
Issue: Jan/Feb 2011 - Volume 15, Number 1
View All Articles in Issue
Page(s): 32-40
Download in electronic PDF format for $75
Abstract: This article reviews pharmaceutical and health implications of the nonenzymatic Maillard reaction, also referred to as browning or N-glycation. The spontaneous Maillard reaction between reducing sugars and amines was first reported by French scientist Louis Maillard in 1912; the Maillard reaction may also occur with other drugs. Hemoglobin A1c and chemically complex colored products that follow initial dextrose and amino acids adducts in parenteral nutrition solutions are the advanced Maillard products most familiar to pharmacists.
Related Keywords: David W. Newton, BS Pharm, PhD, FAPHA, maillard reactions, browning, N-glycation, parenteral nutrition solutions, advanced glycation end products, glycated hemoglobins, oxidation, inflammation, aging, diabetes mellitus, stability, dextrose solutions, reducing sugars
Related Categories: DIABETES, EXCIPIENTS, NUTRITION AND NUTRICEUTICALS, PARENTERALS, STABILITIES, COMPATIBILITIES, ADVERSE DRUG EVENTS